Pretreatment with Antiviral Preparation Kagocel Normalizes the Content of Bone Marrow Multipotent Stromal Cells and TNFα in Blood Serum of CBA Mice Disturbed by Administration of S. typhimurium Antigen Complex In Vivo and Maintains High Concentration of IL-10 and Th1 Cytokines


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

Pretreatment with the active substance of antiviral preparation Kagocel, inductor of type I endogenous IFN, in a daily therapeutic dose (30 μg/mouse) 3 h prior to administration of S. typhimurium antigens to CBA mice reduced the number of bone marrow multipotent stromal cell (significantly increased by 3.2 times on the next day after antigen injection) to the initial level. Thus, activation of the stromal tissue induced by administration of the bacterial antigen was blocked. In addition, preliminary administration of Kagocel modulated the cytokine profile of the blood serum affected by S. typhimurium antigens: reduced 1.6-fold elevated concentration a proinflammatory cytokine TNFα to the control level (in 4 h after antigen injection) and maintained this level in 20 h after antigen administration. Kagocel also maintained the concentration of anti-inflammatory cytokine IL-10 at the level surpassing the normal by 1.6 times and high concentrations of Th1 cytokines (IL-2, IFNγ, and IL-12). These results suggest that Kagocel can reduce the immune response to bacterial antigens (similar to type I IFN [7]), which can contribute to its therapeutic and preventive effects in addition to its well documented antiviral activity and then this preparation can be used for the therapy of diseases accompanied by excessive or chronic inflammation.

作者简介

Yu. Gorskaya

Laboratory for Regulation of Immunity and Immunological Tolerance

编辑信件的主要联系方式.
Email: uliya.gorskaya@nearmedic.ru
俄罗斯联邦, Moscow

A. Suslov

Laboratory of Mediators and Effectors of Immunity, N. F. Gamaleya Federal Research Center for Epidemiology and Microbiology, Ministry of the Healthcare of the Russian Federation

Email: uliya.gorskaya@nearmedic.ru
俄罗斯联邦, Moscow

E. Semenova

Laboratory for Regulation of Immunity and Immunological Tolerance

Email: uliya.gorskaya@nearmedic.ru
俄罗斯联邦, Moscow

M. Konopleva

Laboratory of Mediators and Effectors of Immunity, N. F. Gamaleya Federal Research Center for Epidemiology and Microbiology, Ministry of the Healthcare of the Russian Federation

Email: uliya.gorskaya@nearmedic.ru
俄罗斯联邦, Moscow

V. Nesternko

Laboratory for Regulation of Immunity and Immunological Tolerance

Email: uliya.gorskaya@nearmedic.ru
俄罗斯联邦, Moscow


版权所有 © Springer Science+Business Media, LLC, 2017
##common.cookie##